Modality
siRNA
MOA
IL-17i
Target
IL-23
Pathway
Cell Cycle
SCD
Development Pipeline
Preclinical
~Feb 2011
→ ~May 2012
Phase 1
~Aug 2012
→ ~Nov 2013
Phase 2
~Feb 2014
→ ~May 2015
Phase 3
~Aug 2015
→ ~Nov 2016
NDA/BLA
~Feb 2017
→ ~May 2018
Approved
Aug 2018
→ Oct 2030
ApprovedCurrent
NCT04115043
1,895 pts·SCD
2024-10→2029-05·Completed
NCT05099186
2,384 pts·SCD
2023-09→2030-10·Not yet recruiting
NCT04535266
2,046 pts·SCD
2018-08→2028-08·Not yet recruiting
+1 more trial
9,277 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2028-08-112.4y awayPh3 Readout· SCD
2029-05-043.1y awayPh3 Readout· SCD
2030-10-234.6y awayPh3 Readout· SCD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Not yet…
Approved
Recruit…
Approved
Not yet…
Approved
Complet…
Catalysts
Ph3 Readout
2028-08-11 · 2.4y away
SCD
Ph3 Readout
2029-05-04 · 3.1y away
SCD
Ph3 Readout
2030-10-23 · 4.6y away
SCD
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04115043 | Approved | SCD | Completed | 1895 | PFS |
| NCT05099186 | Approved | SCD | Not yet recr... | 2384 | HbA1c |
| NCT04535266 | Approved | SCD | Not yet recr... | 2046 | ACR20 |
| NCT06288168 | Approved | SCD | Recruiting | 2952 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 |